OptiBiotix Health PLC, formerly Ducat Ventures PLC, is a United Kingdom-based life sciences company developing compounds to tackle obesity, high cholesterol and diabetes. The Company develops a range of compounds which modify the human microbiome (the collective genome of the microbes in the body), to prevent and manage human disease. The Company has a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The product development pipeline is fuelled by its OptiScreen and OptiBiotic platform technologies designed to identify metabolic pathways and compounds. These platforms are applicable across a range of other human diseases.